294 related articles for article (PubMed ID: 35244237)
1. Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2.
Ali F; Alom S; Shakya A; Ghosh SK; Singh UP; Bhat HR
Arch Pharm (Weinheim); 2022 May; 355(5):e2100360. PubMed ID: 35244237
[TBL] [Abstract][Full Text] [Related]
2. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
Zhou Z; Zhu Y; Chu M
Front Immunol; 2022; 13():898192. PubMed ID: 35669787
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
[TBL] [Abstract][Full Text] [Related]
4. Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
El-Shesheny R; El Taweel A; Gomaa MR; Roshdy WH; Kandeil A; Webby RJ; Kayali G; Ali MA
Vaccine; 2022 Jul; 40(32):4303-4306. PubMed ID: 35697574
[TBL] [Abstract][Full Text] [Related]
5. Tracking the COVID-19 vaccines: The global landscape.
Yadav T; Kumar S; Mishra G; Saxena SK
Hum Vaccin Immunother; 2023 Dec; 19(1):2191577. PubMed ID: 36995773
[TBL] [Abstract][Full Text] [Related]
6. Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update.
Wahid M; Jawed A; Mandal RK; Areeshi MY; El-Shall NA; Mohapatra RK; Tuli HS; Dhama K; Pellicano R; Fagoonee S; Haque S
Minerva Med; 2023 Oct; 114(5):683-697. PubMed ID: 37293890
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.
Kakkassery H; Carpenter E; Patten PEM; Irshad S
Trends Mol Med; 2022 Dec; 28(12):1082-1099. PubMed ID: 35999131
[TBL] [Abstract][Full Text] [Related]
8. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.
Francis AI; Ghany S; Gilkes T; Umakanthan S
Postgrad Med J; 2022 May; 98(1159):389-394. PubMed ID: 37066438
[TBL] [Abstract][Full Text] [Related]
9. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022.
Wu N; Joyal-Desmarais K; Ribeiro PAB; Vieira AM; Stojanovic J; Sanuade C; Yip D; Bacon SL
Lancet Respir Med; 2023 May; 11(5):439-452. PubMed ID: 36780914
[TBL] [Abstract][Full Text] [Related]
11. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
[TBL] [Abstract][Full Text] [Related]
12. The current status of COVID-19 vaccines. A scoping review.
Rueda-Fernández M; Melguizo-Rodríguez L; Costela-Ruiz VJ; González-Acedo A; Ramos-Torrecillas J; Illescas-Montes R
Drug Discov Today; 2022 Nov; 27(11):103336. PubMed ID: 35995361
[TBL] [Abstract][Full Text] [Related]
13. Link between COVID-19 vaccines and myocardial infarction.
Zafar U; Zafar H; Ahmed MS; Khattak M
World J Clin Cases; 2022 Oct; 10(28):10109-10119. PubMed ID: 36246837
[TBL] [Abstract][Full Text] [Related]
14. Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks.
Esmaeilzadeh A; Maleki AJ; Moradi A; Siahmansouri A; Yavari MJ; Karami P; Elahi R
Expert Rev Vaccines; 2022 Oct; 21(10):1377-1394. PubMed ID: 35986451
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
16. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
17. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
[TBL] [Abstract][Full Text] [Related]
19. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
[TBL] [Abstract][Full Text] [Related]
20. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
